Compare CVS Health Corp (CVS) vs Centrus Energy Corp (LEU) Price & Performance

CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.

The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.

Centrus Energy (LEU) trades at $147.14, down 4.38% on the day, amid neutral technical signals and mixed earnings performance. The stock shows elevated valuation ratios with a P/E of 75.18 and P/S of 6.68, while profitability metrics include a 10.23% net income margin and 8.05% ROE. Recent news highlights Centrus' strategic positioning as a key supplier of High-Assay Low-Enriched Uranium (HALEU) for advanced nuclear reactors, supported by new multi-year supply contracts with Antares and Radiant announced in September 2026.

The investment case balances strong growth potential in the nuclear fuel market against execution risks and high valuation. Analyst consensus suggests 46% buy ratings with a $218.10 price target, implying significant upside, but investors face risks from cash flow volatility, competitive pressures, and the company's reliance on successful capacity expansion. The recent $500 million stock offering provides capital for growth but may dilute existing shareholders.